Harnessing the power of RNA therapeutics in treating ischemic heart failure: the TRAIN-HEART story.

Ischemic heart disease (IHD) is one of the world's foremost killers, accounting for 16% of all deaths worldwide. IHD is the main cause of heart failure (HF), as it leads to pathological changes in the heart, improper pumping function and eventual death. Therapeutic interventions usually follow a systemic general strategy for all heart failure subtypes due to the lack of a deep understanding of the disease mechanisms.

Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.

COVID-19 is a disease with unique characteristics that include lung thrombosis, frequent diarrhoea, abnormal activation of the inflammatory response and rapid deterioration of lung function consistent with alveolar oedema. The pathological substrate for these findings remains unknown. Here we show that the lungs of patients with COVID-19 contain infected pneumocytes with abnormal morphology and frequent multinucleation.

[Mezlocillin in short-term obstetrico-gynecologic prophylaxis].

The present study examines a sample of 98 patients aged 18-77 (mean age 57) and awaiting obstetric or gynaecological surgery who were given short-term prophylaxis with mezlocillin. The overall success rate was 83.67%, partial success 14.

Clinical experimental considerations on the presence of set uterine pacemakers.

The authors studied the physiology of human uterine muscle contraction. Clinical experimental results obtained from elementary electrophysiological, electrohysterographic and pharmacological studies using PGs suggested that uterine muscle contraction does not originate in "pacemaker" areas. These data also showed that the electric phenomenon is not propagated along preferential "rails".